News

International investors’ eyes on top Finnish health research

Published on: 19/01/2022

International investors’ eyes on top Finnish health research
Ecosystems

The Finnish Health and Life Science Research Showcase for investors, organised now for the second time, bringing together international investors and next-level Finnish future innovation together in December 2021. The event led to over 50 1:1 meetings between investors and research groups.

Now arranged for the second time, the event aimed at boosting the recognition of the Finnish projects, introducing researchers to international investors, promoting awareness of available funding opportunities as well as putting interesting projects – that are still at the research stage – on the investors’ collective radar.

The annually held event is co-organized by four parties: Health Capital Helsinki, Business Finland, Business Finland Venture Capital and Tesi (Finnish Industry Investment Ltd).

Altogether, the event introduced 22 promising research projects from Finnish universities to 21 international and 10 Finnish investors. The investors got to listen to the pitches of the most prominent health and life science focused research groups of the Finnish universities – some of them returning from the previous year’s event.

The event gives investors a ‘sneak peek’ at what’s cooking in the best universities in Finland.

Productive one-on-one meetings

This year, the event had added an important feature: investors now had the possibility for 1:1 meetings with the research groups right after their pitches. These meetings turned out to be a big hit as there was a total of 53 one-on-ones.

One of the experts making a pitch was professor Tero Järvinen from Tampere University. Järvinen, who presented the project DecoDerma at the event, said that the commercialization of the project is still at its early stages.

“We will continue to search for funding in the near future and move our molecule to clinical trials,” said Järvinen.

Järvinen was making a pitch at the event now for the second time, having had the opportunity to present the same case to the investors last year, as well.

“This year, we again received highly valuable experience. A large number of investors were interested in our project and we had multiple productive one-on-one meetings with the investors,” Järvinen looks back at the event.

Harriet Gullstén, Business Finland

Rauni Korolainen / Business Finland

Senior Advisor Harriet Gullstén from Business Finland hosted the second day of the event.

Ground-breaking innovation, hard science and patient outcomes on investors’ radar

Speaking at the event, Stephanie Munk from Danish VC company Sunstone Life Science Ventures commented that Finland – and Nordics, in general – have a lot of things going for them: free education, strong universities and networks that support the birth of various innovations. Furthermore, Nordic innovation hubs/clusters have performed convincingly in Health & Wellbeing and investors are taking note in numbers.

“Because of these reasons, European and US investors are looking at Scandinavia for investment opportunities in healthcare and other sectors,” said Munk.

Talking about what Sunstone is looking for in an investment project, Munk said that ground-breaking innovation is obviously the number one thing. If the project is rooted in hard science and able to deliver an improved patient outcome, the prospects are rather promising from the get-go.

“In addition, the team must be competent and ambitious enough and it must have a solid master plan,” Munk concluded.

Nordic innovation hubs have performed convincingly in Health & Wellbeing and investors are taking note in numbers.

© Eeva Anundi / Business Finland

“Finnish health sector may still suffer from a slight case of ‘best kept secret’.”

Finnish science needs more exposure

Investment Director Joni Karsikas from Tesi believes that Finnish health sector may still suffer from a slight case of “best kept secret” – looking at things from Central Europe, for example, Finland is a fringe market.

“We have great science projects with genuine commercial potential here, but we need to get our researchers into the limelight a lot more,” he said.

According to Karsikas, the Finnish Health and Life Science Research Showcase is valuable for doing just that: investors get a “sneak peek” at what’s cooking in the best universities in Finland.

“Also, as the event was now held for the second time, you see the progress certain projects have made in a year – and there’s real consistency there. This bodes well for the eventual commercial opportunities, as well.”

Oscar Castanon, Analyst at Argobio Studio, based in France, participated in the event and definitely liked what he saw.

“The Finnish Health and Life Science Research Showcase was very well organized and helped us identify key researchers with projects fitting our interests,” Castanon comments.

“We hope that some of these projects will lead to future collaborations,” he adds.

Text: Sami J. Anteroinen

More information:

Lauri Kuronen

Lauri Kuronen

Senior Business Advisor, Health Capital Helsinkilauri.kuronenhealthcapitalhelsinki.fi+358 40 575 1847

NEWS​

Related News

New Round Tables announced to drive progress on EHDS and health AI

3 Jul 2025

The European Accessibility Act Is Here. Are You Ready?

2 Jul 2025
Why inclusive design is no longer optional – and how Big Motive can help you lead the way.

DTH-Lab Director: The G7 must act now to address the digital health transformation

2 Jul 2025
As digital platforms increasingly shape health systems and information flows, the G7 must lead in setting global standards to ensure safety, equity an...

InnoHSupport Open Calls

1 Jul 2025
Welcome to the InnoHSupport Open Calls!

Transformative Health Instrument Call 2025

1 Jul 2025
Apply to the Transformative Health Instrument (THI) Call 2025 if you are a growing and innovative healthcare start-up working on solutions that have s...

Longitude Prize on ALS

1 Jul 2025
The £7.5 million (~$10 million) Longitude Prize on ALS incentivises the use of AI-based approaches to transform drug discovery for amyotrophic lateral...

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *